According to a recent LinkedIn post from Autoimmunity BioSolutions, the company has closed a $1 million seed extension round, bringing total seed capital to $3.1 million. The post notes participation from existing backers EOS BioInnovation, Independent Capital and Elmstead Partners, alongside new investor NewTech Investment Holdings, described as a family office.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests that the new funding will be directed toward animal model work and patient biosample analyses in the company’s lead indication of rheumatoid arthritis. For investors, this additional seed capital may extend the company’s R&D runway, potentially de-risking early-stage development while positioning Autoimmunity BioSolutions to generate proof-of-concept data in autoimmune diseases.
The post also highlights investor conviction in what is described as a differentiated scientific platform aimed at patients not well served by current autoimmune therapies. If the planned studies yield compelling data, the company could strengthen its case for future financing rounds or strategic partnerships, though the current update relates only to preclinical and exploratory work and does not indicate near-term revenue prospects.